Map suspends development of asthma treatment after partner pulls out(0)
Map Pharmaceuticals of Mountain View said today it has suspended development of its drug candidate aimed at asthma in children after its development partner, AstraZeneca terminated its license agreement related to Unit Dose Budesonide. Earlier this year results from a Phase 3 clinical trial of the drug candidate failed to meet expectations in either Read the rest of this entry »
Subscribe via RSS all feeds